Federal lawmakers are set to receive a key briefing on kratom regulation as uncertainty persists nearly a year after the FDA differentiated synthetic 7-hydroxymitragynine (7-OH) from natural kratom. Despite the agency’s 2025 recommendation to regulate synthetic compounds, no unified federal framework has emerged, prompting a patchwork of state-level policies.
The American Kratom Association will lead the June 3 session, bringing together scientists and policy specialists to explain the implications of the FDA’s stance and ongoing regulatory gaps. With an estimated 20 million Americans using kratom, advocates say clearer federal guidance is urgently needed.
Discussion will also focus on proposed legislation aimed at establishing consumer protections while maintaining access to natural products.
